Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Subscribe To Our Newsletter & Stay Updated
